Funding and Investments

Jan 01, 2018
BioPharm International
Gene therapies highlight FDA new drug approvals in 2017.
Jan 01, 2018
BioPharm International
BioPharm International will mark 30 years of biopharma industry progress and challenges in 2018.
Dec 12, 2017
By BioPharm International Editors
The partnership aims to develop and commercialize a skin-care drug candidate being developed to treat actinic keratosis, which, left untreated, can progress to cancer.
Dec 08, 2017
By BioPharm International Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Dec 06, 2017
By BioPharm International Editors
The company will expand two of its Ohio facilities, investing approximately $145 million to support manufacturing and warehouse operations.
Dec 01, 2017
By BioPharm International Editors
Lonza has entered into strategic license agreements for exclusive rights to a gene-therapy platform for developing treatments for hearing and balance disorders.
Nov 28, 2017
By BioPharm International Editors
The joint venture will focus on the discovery, development, and commercialization of potential new drugs for the global market as well as speed delivery of new medicines to China.
Nov 16, 2017
By BioPharm International Editors
The entities announced that they will partner to improve access to cancer treatments and diagnostics in Ethiopia, Uganda, and Tanzania.
Oct 24, 2017
By BioPharm International Editors
The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.
Oct 12, 2017
By BioPharm International Editors
NIH has entered a five-year, $215-million collaboration with leading biopharmaceutical companies to advance the development of cancer immunotherapies.
native1_300x100
lorem ipsum